A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia-Reference-Cited by-同舟云学术

A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia

Published:2014-04 Issue:1-3 Volume:154 Page:14-22
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Meltzer H.Y.,Lindenmayer J.-P.,Kwentus J.^ORCID,Share D.B.,Johnson R.,Jayathilake K.

Funder

Janssen Scientific Affairs, LLC

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference58 articles.

1. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia;Azorin;Am. J. Psychiatry,2001

2. A rating scale for drug-induced akathisia;Barnes;Br. J. Psychiatry,1989

3. Neurobiology of treatment-resistant schizophrenia: new insights and new models;Beerpoot;Eur. Neuropsychopharmacol.,1996

4. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia;Bitter;Prog. Neuropsychopharmacol. Biol. Psychiatry,2004

5. Risperidone versus clozapine in treatment- resistant chronic schizophrenia: a randomized double- blind study;Bondolfi;The Risperidone Study Group. Am. J. Psychiatry,1998

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine;The Journal of Clinical Psychiatry;2024-05-01

2. Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes;Biomedicines;2024-01-12

3. Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety;Neuropsychiatric Disease and Treatment;2023-10

4. The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up;Biomedicines;2022-12-24

5. Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials;Schizophrenia Bulletin;2022-02-08